Large pharmaceutical companies cut pipelines in 2023
Click:
256 Update time：2023-02-10 【
Close】
Several companies, including GSK, Janssen, Novartis and Pfizer, announced that they would cut the pipeline when releasing the full year financial results in 2022. The following drugs were removed from the pipelines of these companies.
——Bristol-Myers Squibb
Anti-CTLA-4 NF: The oncology monoclonal antibody candidate BMS-986218 targeting human T-cell receptor cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) is in phase 2.
Anti-CTLA-4 body treatment: Oncological antibody targeting CTLA-4 is in phase 2. BMS cooperated with CytomX Therapeutics to develop an antibody named BMS-986249.
Anti-SIRP in solid tumors α： Anti-signal regulatory protein called CC-95251- α The candidate drug is in phase 1.
Branebrutinib: The small molecular covalent inhibitor of Bruton tyrosine kinase is in phase 2. It is also known as BMS-986195.
Cendakimab: Bristol Myers said that it would no longer develop its atopic dermatitis antibody, which has completed phase 2 research. Samit Hirawat, the chief medical officer of the company, said that although the study reached its main end point, the treatment field of atopic dermatitis was very crowded, and the centakimab had no significant advantages over these existing options.
IL-12 Fc: known as DF6002 and BMS-986415 are tumor candidate drugs with univalent IL-12 immunoglobulin Fc fusion protein, which is in phase 1.
MK2 inhibitor in ankylosing spondylitis: the immunological candidate drug CC-99677 is in phase 2. It is introduced in the research and treatment of arthritis.
New molecular entity: The undisclosed fibrosis candidate drug is in phase 1.
ROR1 CAR-T: Hematology candidate drugs obtained from Juno Therapeutics are in the first stage. It is also known as JCAR-024.
STING agonist: The agonist of interferon gene stimulator (STING) protein is in phase 1. Tumor candidate drugs are also known as BMS-986301.
——GlaxoSmithKline
GSK3915393: GlaxoSmithKline said on the quarterly earnings conference call that it had canceled GSK3915393, the glutamine transferase 2 (TG2) inhibitor. The company believes that GSK3915393 has the potential of celiac disease. The safety, tolerance and pharmacokinetics of the drug were studied in Phase 1.
GSK3915393: GlaxoSmithKline said on the quarterly earnings conference call that it had stopped the research and development of transglutaminase 2 (TG2) inhibitor GSK3915393. The company once believed that GSK3915393 had the potential to treat celiac disease. The safety, tolerance and pharmacokinetics of the drug were studied in the first stage. Belantamab and GSK3878858A: The company has also withdrawn several other candidate drugs from its pipeline, including Belantamab mafodotin (GSK2857916), an anti-BCMA antibody for third-line multiple myeloma. It also abandoned GSK3878858A, a recombinant protein vaccine against Staphylococcus aureus, which is in phase 2 research.
GSK4362620A: GlaxoSmithKline also stopped GSK4362620A, a COVID-19 plant-derived virus-like particle vaccine, called Covifenz. GlaxoSmithKline has been developing vaccines jointly with Medicago, but has mentioned "major manufacturing problems" in preventing the use of vaccines.
——Yang Sen
JNJ-6358 and JNJ-8902: The company has decided to cancel the priority of oncology dual-specific JNJ-6358 and prostate cancer candidate JNJ-8902. Neither of them appears in the company's latest pipeline overview. However, the trials of these two candidate drugs are still in progress.
JNJ-6358 binds CD3 on T cells and human leukocyte antigen G (HLA-G) on cancer cells, while JNJ-8902 is CD3 x TMEFF2 bispecific.
——Merck
Chikungunya vaccine: The company has abandoned Chikungunya vaccine, which is a virus infection transmitted by mosquitoes. Merck obtained the candidate vaccine from the acquisition of Themis Bioscience in 2020. The vaccine was studied in phase 2 clinical trials. Emergent Biosolutions continued to develop candidate vaccines for chikungunya fever.
Indications for Lenvima glioblastoma: Merck is also stopping using Lenvima (lenvatinib) to target glioblastoma. As part of its LEAP program, it has been testing with Keytruda (pembrolizumab). Eisai is a partner of LEAP program, which also focuses on triple negative breast cancer cancer, ovarian cancer, gastric cancer, colorectal cancer, biliary cancer and pancreatic cancer.
——Novartis
GSK3915393: GlaxoSmithKline said on the quarterly earnings conference call that it had canceled GSK3915393, the glutamine transferase 2 (TG2) inhibitor. The company believes that GSK3915393 has the potential of celiac disease. The safety, tolerance and pharmacokinetics of the drug were studied in Phase 1.
Cosentyx: Novartis said it had abandoned the phase 3 study of Cosentyx (secukinumab), which is an IL-17A antibody for the treatment of active peripheral spinal arthritis. According to the statement of clinicaltrials.gov, the experiment was "terminated due to the strategic decision of senior management".
Branaplam: The company also said in the 2022 interim income report that it would eliminate its Branaplam plan after reviewing the potential income risk of the phase 2 VIBRANT-HD study for adults with Huntington's chorea. In August, Novartis suspended the phase 2b study of branaplam after discovering the potential relationship between the candidate drug and peripheral neuropathy.
The company also tested candidate drugs in a phase 2 study involving patients with spinal muscular atrophy.
——Pfizer
Recipe/other indications for Paxlovid: This large pharmaceutical company announced that it would stop eight projects, including Recipe for achondroplasia (dwarfism) and two indications for COVID-19 antiviral Paxlovid.
Other projects: Pfizer has also given up a drug for treating autoimmune diseases, which has obtained the qualification of orphan drug for treating chronic inflammatory demyelinating polyneuropathy, and a biological agent for treating solid tumors. Finally, it also terminated kinase inhibitors used to treat melanoma and metastatic breast cancer.
